CGON.US CG Oncology, Inc. Common stock

Healthcare Biotechnology USA Stocks
74.40 USD
Close of Nov 14, 2026
37.01 80.97
Market cap
USD 6.65B
P/E
-
P/B
6.33x
ROE
-26.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CGON.US undervalued?

Graham number

The Graham number of CG Oncology, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CG Oncology, Inc. Common stock fundamental analysis

No fundamental analysis for CG Oncology, Inc. Common stock yet.

CG Oncology, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CG Oncology, Inc. Common stock

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy i…

Full company profile